Skip to main content
. Author manuscript; available in PMC: 2021 Mar 10.
Published in final edited form as: Ann Oncol. 2020 Feb 20;31(5):590–598. doi: 10.1016/j.annonc.2020.02.008

Figure 2. Single nucleotide variant (SNV) and copy number variant (CNV) events in 20 genes from PARPi/platinum resistance pathways.

Figure 2.

Co-mutation plot showing SNV and CNV events in 20 genes from pathways previously implicated in resistance to poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) or platinum, across 15 metastatic breast cancer tumor samples obtained either before or after the acquisition of resistance to PARPi or platinum. Each column of data represents a unique tumor specimen; each row represents a gene of interest. No pre-resistance tumor sample was available for sequencing in patient 303. Horizontal tracks along the top of the plot indicate select clinical parameters for each specimen, presence or absence of detected BRCA reversion in either tumor tissue or circulating tumor DNA, and presence or absence of RAD51 foci staining.

Neg, negative; Pos, positive; Undef, undefined.